
Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2024
Description
Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2024
DelveInsight’s, “Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Methicillin-Resistant Staphylococcus Aureus Infections: Overview
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens. The same organism that lives as a commensal and is transmitted in both health-care and community settings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and hospital-acquired infections. Genetically diverse, the epidemiology of MRSA is primarily characterized by the serial emergence of epidemic strains. Although its incidence has recently declined in some regions, MRSA still poses a formidable clinical threat, with persistently high morbidity and mortality. Successful treatment remains challenging and requires the evaluation of both novel antimicrobials and adjunctive aspects of care, such as infectious disease consultation, echocardiography and source control.
""Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape is provided which includes the disease overview and Methicillin-Resistant Staphylococcus Aureus Infections treatment guidelines. The assessment part of the report embraces, in depth Methicillin-Resistant Staphylococcus Aureus Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Methicillin-Resistant Staphylococcus Aureus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Methicillin-Resistant Staphylococcus Aureus Infections R&D. The therapies under development are focused on novel approaches to treat/improve Methicillin-Resistant Staphylococcus Aureus Infections.
This segment of the Methicillin-Resistant Staphylococcus Aureus Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Methicillin-Resistant Staphylococcus Aureus Infections Emerging Drugs
- HY-004B8b: Helperby Therapeutics
- TRL1068: Trellis Bioscience
- Delpazolid (LCB01-0371): LegoChem Biosciences
Further product details are provided in the report……..
Methicillin-Resistant Staphylococcus Aureus Infections: Therapeutic Assessment
This segment of the report provides insights about the different Methicillin-Resistant Staphylococcus Aureus Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Methicillin-Resistant Staphylococcus Aureus Infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Methicillin-Resistant Staphylococcus Aureus Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Methicillin-Resistant Staphylococcus Aureus Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Methicillin-Resistant Staphylococcus Aureus Infections drugs.
Methicillin-Resistant Staphylococcus Aureus Infections Report Insights
- Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Methicillin-Resistant Staphylococcus Aureus Infections drugs?
- How many Methicillin-Resistant Staphylococcus Aureus Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Methicillin-Resistant Staphylococcus Aureus Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Methicillin-Resistant Staphylococcus Aureus Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Methicillin-Resistant Staphylococcus Aureus Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Trellis Bioscience
- LegoChem Biosciences
- Aptorum Group
- ContraFect
- Crystalgenomics
- Cellics Therapeutics
- MicuRx
- Oxford Antibiotic Group
- Destiny Pharma
- TSRL, Inc.
- TAXIS Pharmaceuticals
- Basilea Pharmaceutica
- Helperby Therapeutics
- Akagera Medicines
- Histogen
- Alphamab Co. Ltd
- Biocidium Pharmaceuticals
- TRL1068
- Delpazolid
- ALS 4
- Tonabacase
- Teicoplanin inhalation
- Research programme: antibacterials
- LTX 109
- CG 400549
- Research programme: anti-infective monoclonal antibodies
- SAAP 148
- Exebacase
- Marinus
- CTI 005
- Iclaprim
- MRX 4
- MRX 7
- XF-73
- TXA709
- ARV-1801
- AR-301
- ACX-375C
- ABX-605
- IBT-V02
- BCM-0184
Table of Contents
100 Pages
- Introduction
- Executive Summary
- Methicillin-Resistant Staphylococcus Aureus Infections: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Methicillin-Resistant Staphylococcus Aureus Infections – DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase II)
- Comparative Analysis
- HY-004: Helperby therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- TRL1068: Trellis Bioscience
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- EVX B1: Evaxion Biotech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
- Methicillin-Resistant Staphylococcus Aureus Infections Key Products
- Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
- Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
- Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
- Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
- Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.